奥拉帕利剂量减少和治疗中断对SOLO2/ENGOT-ov21铂敏感复发性卵巢癌治疗结局的影响
基于SOLO2试验数据,评估奥拉帕利维持治疗前12周剂量调整对铂敏感复发性卵巢癌患者生存结局的影响,并分析基线特征与剂量调整的关联。结果显示,前12周因不良事件进行的剂量减少和中断未影响无进展生存期和总生存期。
要点
- 前12周奥拉帕利剂量减少或中断未显著影响无进展生存期和总生存期。
- 基线体能状态1、任何恶心、体重≤70 kg与相对剂量强度≤90%风险增加相关。
- 因不良事件需减量或中断时,可告知患者结局不会受到不利影响。
核心结论
- 前12周因管理奥拉帕利相关不良事件而进行的剂量减少和中断未影响无进展生存期和总生存期。
- 当因不良事件需要减量或中断时,本研究结果有助于向患者保证其结局不会受到不利影响。
研究设计与样本
- 基于SOLO2试验数据的分析,纳入185例接受奥拉帕利治疗的患者进行12周界标分析。
- 计算前12周相对剂量强度(RDI),定义为接受剂量占标准剂量(300 mg每日两次)的百分比。
- 将患者分为RDI >98%、RDI 90%-98%和RDI <90%三组。
- 采用12周界标Cox回归分析RDI分类与无进展生存期和总生存期的关联。
- 采用逻辑回归分析基线因素与12周RDI的相关性。
主要发现
- 界标分析纳入185例患者,12周平均RDI为91.4%。
- RDI >98%组(n=110)、90%-98%组(n=29)和<90%组(n=45)的中位无进展生存期分别为14.2、19.3和34.4个月,P=0.37。
- 三组的中位总生存期分别为49.7、49.5和54.1个月,P=0.84。
- 基线体能状态1与RDI≤90%风险增加相关(OR:2.54;95%CI:1.11-5.82)。
- 任何恶心(OR:3.17;95%CI:0.9-11.23)和体重≤70 kg(OR:1.86;95%CI:0.92-3.76)与RDI≤90%风险增加相关。
临床怎么用
- 作者认为,当因不良事件需要减量或中断时,本研究结果有助于向患者保证其结局不会受到不利影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maintenance treatment with poly (ADP-ribose) polymerase (PARP) inhibitor is now the standard of care in patients with BRCA-mutated platinum-sensitive recurrent ovarian cancer following response to chemotherapy. In the SOLO2 trial, adverse event (AE)-associated olaparib interruption, dose reduction, and discontinuation occurred in 50%, 28%, and 17% of patients, respectively. We used data from the SOLO2 trial to evaluate the impact of dose alterations on survival outcomes and identified baseline characteristics associated with dose alteration. PATIENTS AND METHODS: We computed relative dose intensity (RDI) defined as the received dose as a percentage of the standard dose (300 mg twice a day) during the first 12 weeks on treatment. Patients were categorized into RDI >98%, RDI 90%-98%, and RDI <90%. The association between RDI categories with progression-free survival (PFS) and overall survival (OS) were examined using a 12-week landmark Cox regression analysis. Logistic regression analysis was used to correlate baseline factors with RDI at 12 weeks. RESULTS: In patients on olaparib included in the landmark analysis (n = 185), the mean 12-week RDI was 91.4%. There was no significant difference across 12-week RDI >98% (n = 110), 90%-98% (n = 29), and <90% (n = 45) categories for PFS (median, 14.2 versus 19.3 versus 34.4 months; P = 0.37) and OS (median, 49.7 versus 49.5 versus 54.1 months; P = 0.84). Risk of RDI ≤90% increased with baseline performance status 1 [odds ratio (OR): 2.54; 95% confidence interval (CI): 1.11-5.82] any nausea (OR: 3.17; 95% CI: 0.9-11.23), and with body weight ≤70 kg (OR: 1.86; 95% CI: 0.92-3.76). CONCLUSIONS: Dose reduction and interruption for the management of olaparib-associated AEs during the first 12 weeks did not impact on PFS and OS. When counselling patients requiring dose reductions or interruptions due to AEs, the results of this study will help assure patients that their outcomes will not be adversely affected.
引用
- Francis KE, Kim SI, Friedlander M, et al. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. Ann Oncol. 2022. PMID: 35219776. doi:10.1016/j.annonc.2022.02.222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。